Skip to content
Geriatric Assessment Improved Outcomes for Older Patients with Cancer

Geriatric Assessment Improved Outcomes for Older Patients with Cancer

Get the podcast

CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number

The Audio Journal of Oncology

CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in higher scores of patient satisfaction—which the investigators regarded as paramount among therapy outcomes. (https://meetinglibrary.asco.org/record/159519/abstract)

In a media briefing about the study held at the 2018 Annual Meeting of the American Society of Clinical Oncology lead author Supriya Gupta Mohile MD MS, the Wehrheim professor of medicine and surgery and director of geriatric oncology at the University of Rochester, New York, emphasized the pivotal role of GA when treating older patients for their late-stage cancers. She talks with the Audio Journal of Oncology.

Tags

advanced cancer geriatric assessmentgeriatric assessment for cancergeriatric oncology

Next in ASCO 2018

All 10 interviews

Interview 8 of 10

Gender Disparity in Head and Neck Cancer Treatment and Outcomes

Gender Disparity in Head and Neck Cancer Treatment and Outcomes

CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa

9 June 2018

Related Episodes

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial

CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA

15 Oct 2026
6 min
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries

CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.

8 Sep 2026
9 min
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy

CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.

31 Aug 2026
13 min